BioMarin Pharmaceutical (BMRN) AI Stock Analysis

• Market Cap: $13.55B
• Dividend Yield: N/A
• Average Volume (3M): 1.58M
• Price to Earnings (P/E): 32.1
• Beta (1Y): 0.41
• Revenue Growth: 17.35%
• EPS Growth: 151.40%
• Country: US
• Employees: 3,401
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): 2.20
• Shares Outstanding: 190,777,050
• 10 Day Avg. Volume: 1,927,803
• 30 Day Avg. Volume: 1,577,615
• PEG Ratio: 0.21
• Price to Book (P/B): N/A
• Price to Sales (P/S): 4.75
• Price to Cash Flow (P/CF): 18.30
• P/FCF Ratio: 20.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $99.00
• Price Target Upside: 40.41% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 24

BioMarin Pharmaceutical demonstrates strong financial health with significant revenue and profitability growth, supported by robust cash flow. Positive technical indicators and a promising earnings call contribute to the stock's attractiveness. However, its high P/E ratio suggests a premium valuation, and the lack of a dividend yield could deter income-focused investors. Rising liabilities and increased SG&A expenses are potential risks to monitor.

Positive Factors

Financial Performance

BMRN beat expectations by reporting total sales of $747M in 4Q24 which is higher than projections of $712/$708M that represents a +16% YoY growth.

Product Growth

Management delivered impressive 56% YoY Voxzogo growth driven by expanding prescriber base and increasing penetration in the U.S. and other markets.

Negative Factors

Legal Risks

Potential legal action against ASND on Voxzogo IP could impact product deployment in multiple EU countries.

BioMarin Pharmaceutical Business Overview & Revenue Model

Company Description

BioMarin Pharmaceutical Inc. is a biotechnology company that specializes in developing and commercializing innovative biopharmaceuticals for serious diseases and medical conditions. Primarily operating in the healthcare sector, BioMarin focuses on rare genetic disorders, leveraging its expertise in enzyme replacement therapies, gene therapies, and small molecule drugs. Its core products include treatments for conditions such as phenylketonuria (PKU), mucopolysaccharidosis (MPS), and other rare diseases, with its therapies aiming to address unmet medical needs.

How the Company Makes Money

BioMarin Pharmaceutical generates revenue through the development, production, and sales of its pharmaceutical products. The company's primary revenue streams come from the commercial sales of its approved therapies, such as Kuvan and Palynziq for PKU and Vimizim for MPS IV. BioMarin also earns money through collaborations and licensing agreements with other pharmaceutical companies, leveraging its proprietary research and development capabilities. Additionally, the company may receive milestone payments and royalties from partnered products. Key factors contributing to its earnings include successful product launches, regulatory approvals, and the expansion of its product pipeline addressing rare and underserved medical conditions.

BioMarin Pharmaceutical Financial Statement Overview

Summary

BioMarin Pharmaceutical showcases strong financial health with impressive revenue growth and profitability improvements. The balance sheet reflects solid equity and manageable leverage, though rising liabilities warrant attention. Robust cash flow generation underpins the company's ability to fund operations and growth strategically. Overall, the company is well-positioned for continued success in the biotechnology sector.

Income Statement

BioMarin Pharmaceutical has demonstrated robust revenue growth with a significant increase from $1.70 billion in 2019 to $2.85 billion in 2024, indicating strong market demand and successful product offerings. The gross profit margin is excellent, maintaining high levels consistently over the years. Net profit margin has improved significantly, reflecting better cost management and operational efficiency. The EBIT and EBITDA margins have also shown substantial improvement, translating into stronger operational profitability.

Balance Sheet

The company maintains a healthy balance sheet with a solid equity base; the equity ratio indicates strong capitalization with stockholders' equity consistently covering total assets. The debt-to-equity ratio is reasonable, demonstrating manageable leverage levels. Return on Equity has improved, showcasing better utilization of equity capital. However, the company's total liabilities have been increasing, which requires careful monitoring to maintain financial stability.

Cash Flow

Cash flow generation has improved, with a strong increase in free cash flow indicating better operational cash management. The operating cash flow to net income ratio suggests efficient conversion of earnings into cash. The free cash flow to net income ratio further highlights the company's ability to generate cash beyond its net earnings, supporting future growth initiatives and reducing financial risk.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.75B	2.85B	2.42B	2.10B	1.85B	1.86B
	Gross Profit
2.14B	2.27B	1.84B	1.61B	1.38B	1.34B
	EBIT
313.43M	484.21M	194.44M	57.55M	-60.01M	-96.26M
	EBITDA
507.32M	484.21M	310.28M	267.51M	48.03M	-5.85M
	Net Income Common Stockholders
322.29M	426.86M	167.65M	141.56M	-64.08M	854.03M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.14B	1.14B	1.07B	1.29B	1.01B	1.07B
	Total Assets
6.99B	6.99B	6.84B	6.38B	6.00B	5.85B
	Total Debt
595.14M	595.14M	1.10B	1.08B	1.08B	1.08B
	Net Debt
-347.70M	-347.70M	340.62M	358.49M	491.80M	425.99M
	Total Liabilities
1.33B	1.33B	1.89B	1.77B	1.73B	1.74B
	Stockholders Equity
5.66B	5.66B	4.95B	4.60B	4.27B	4.11B
Cash Flow		Free Cash Flow
300.88M	487.42M	51.65M	44.36M	185.31M	-52.15M
	Operating Cash Flow
414.70M	572.84M	159.26M	175.90M	304.54M	85.36M
	Investing Cash Flow
-4.88M	136.49M	-111.24M	-20.03M	-366.31M	-53.62M
	Financing Cash Flow
-518.47M	-526.45M	-18.73M	-18.65M	-48.00K	181.12M

BioMarin Pharmaceutical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 70.51
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRN, the sentiment is Positive. The current price of 70.51 is above the 20-day moving average (MA) of 66.79, above the 50-day MA of 65.50, and below the 200-day MA of 74.05, indicating a neutral trend. The MACD of 1.72 indicates Negative momentum. The RSI at 63.94 is Neutral, neither overbought nor oversold. The STOCH value of 86.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BMRN.

BioMarin Pharmaceutical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
REGN	78 Outperform	$73.85B	17.62	15.03%	0.13%	8.27%	10.35%
BMRN	77 Outperform	$13.55B	32.06	7.54%	―	17.35%	151.40%
VRTX	64 Neutral	$123.21B	―	-3.26%	―	11.64%	-114.72%
RARE	54 Neutral	$3.80B	―	-222.95%	―	29.01%	23.93%
ALNY	50 Neutral	$31.45B	―	-414.62%	―	22.97%	38.54%
Sector *	49 Neutral	$7.05B	0.34	-55.09%	2.46%	25.27%	-3.43%
IONS	49 Neutral	$5.24B	―	-77.15%	―	-10.48%	-18.79%

BioMarin Pharmaceutical Corporate Events

BioMarin Expands Board with New Independent Director

On February 20, 2025, BioMarin Pharmaceutical’s Board of Directors expanded from eleven to twelve members, appointing Timothy P. Walbert as an independent director effective February 24, 2025. Mr. Walbert will receive standard director fees and a pro rata share of the 2024 annual award of $400,000 in restricted stock units, with shares vesting before the next annual meeting of stockholders. This appointment does not result from any arrangement or related party transaction.